Pamela Ermine, DO
Family Medicine · Boynton Beach, FLNPI 1508887506
Payments from drug & device makers
Across 431 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$919
- Lilly USA, LLC$637
- Amgen$635
- AstraZeneca$634
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$394
- plus $3K from 33 others
What the payments were for
- Food & beverage$7,587100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 71 | $1,003 |
| AbbVie(2 entities) | 53 | $919 |
| Lilly USA, LLC | 42 | $637 |
| Amgen | 37 | $635 |
| AstraZeneca | 37 | $634 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 21 | $394 |
| Bayer | 21 | $345 |
| Pfizer | 14 | $269 |
| GSK | 11 | $204 |
| Boston Scientific | 3 | $169 |
| Kowa Pharmaceuticals America, Inc. | 9 | $164 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $162 |
| Exact Sciences | 7 | $160 |
| Novartis | 8 | $153 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $144 |
| Merck | 9 | $144 |
| Avanir Pharmaceuticals, Inc. | 6 | $136 |
| Astellas Pharma US Inc | 6 | $123 |
| Amarin Pharma, Inc. | 6 | $111 |
| Boehringer Ingelheim | 5 | $110 |
| Exactech, Inc. | 1 | $100 |
| Idorsia Pharmaceuticals US Inc | 5 | $98 |
| Currax Pharmaceuticals LLC | 7 | $98 |
| Eisai Inc. | 3 | $79 |
| Arbor Pharmaceuticals, Inc. | 4 | $75 |
| Optinose US, Inc. | 3 | $67 |
| Otsuka America Pharmaceutical, Inc. | 3 | $56 |
| Radius Health, Inc. | 3 | $54 |
| Johnson & Johnson | 3 | $50 |
| Edwards Lifesciences | 1 | $42 |
| Nalpropion Pharmaceuticals LLC | 3 | $39 |
| Lundbeck LLC | 2 | $39 |
| Esperion Therapeutics, Inc. | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Nevro Corp. | 1 | $28 |
| Noven Therapeutics, LLC | 1 | $22 |
| Gilead | 1 | $21 |
| Bardy Diagnostics, Inc. | 2 | $18 |
| Dexcom, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NOVATION HIP$100
How this compares
$7,587 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 194 | $250,906 |
| OzempicSemaglutide | 151 | $202,099 |
| JardianceEmpagliflozin | 140 | $169,867 |
| FarxigaDapagliflozin Propanediol | 103 | $118,581 |
| RybelsusSemaglutide | 49 | $82,261 |
| XareltoRivaroxaban | 43 | $63,338 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $52,098 |
| WegovySemaglutide | 26 | $38,557 |
| ProliaDenosumab | 17 | $28,751 |
| JanuviaSitagliptin Phosphate | 26 | $28,356 |
| EntrestoSacubitril/Valsartan | 17 | $24,775 |
| EliquisApixaban | 14 | $22,615 |
| Repatha SureclickEvolocumab | 25 | $17,200 |
| BelsomraSuvorexant | 20 | $16,623 |
| Repatha SyringeEvolocumab | 18 | $14,113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $1,003 | $322,918226 claims |
| Lilly USA, LLCMounjaro | $637 | $250,906194 claims |
| Boehringer IngelheimJardiance | $110 | $169,867140 claims |
| AstraZenecaFarxiga | $634 | $118,581103 claims |
| Johnson & JohnsonXarelto | $50 | $63,33843 claims |
| MerckJanuvia, Belsomra, Janumet | $144 | $56,00566 claims |
| GSKTrelegy Ellipta | $204 | $52,09853 claims |
| AmgenProlia | $635 | $28,75117 claims |
| PfizerEliquis, Premarin | $269 | $25,24227 claims |
| NovartisEntresto | $153 | $24,77517 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $164 | $10,32420 claims |
| AbbVieSynthroid | $919 | $9,875108 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Boynton Beach
- Rasha YoussefBoynton Beach$7.4M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.